APA (7th ed.) Citation

Azad, A., Fizazi, K., Matsubara, N., Saad, F., De Giorgi, U., Joung, J. Y., . . . Agarwal, N. (2026). Corrigendum to “Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study” [Eur J Cancer 213 (December) (2024) 115078]. European journal of cancer, 232, . https://doi.org/10.1016/j.ejca.2025.116106

Chicago Style (17th ed.) Citation

Azad, Arun, et al. "Corrigendum to “Talazoparib Plus Enzalutamide in Metastatic Castration-resistant Prostate Cancer: Safety Analyses from the Randomized, Placebo-controlled, Phase III TALAPRO-2 Study” [Eur J Cancer 213 (December) (2024) 115078]." European Journal of Cancer 232 (2026). https://doi.org/10.1016/j.ejca.2025.116106.

MLA (9th ed.) Citation

Azad, Arun, et al. "Corrigendum to “Talazoparib Plus Enzalutamide in Metastatic Castration-resistant Prostate Cancer: Safety Analyses from the Randomized, Placebo-controlled, Phase III TALAPRO-2 Study” [Eur J Cancer 213 (December) (2024) 115078]." European Journal of Cancer, vol. 232, 2026, https://doi.org/10.1016/j.ejca.2025.116106.